Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia Study of XT1061 in Healthy Subjects
NCT06280534Phase 1Recruiting
- Sponsor
- Xi'an Xintong Pharmaceutical Research Co., Ltd.
- Start
- Jul 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of XT1061 in Chronic Hepatitis B (CHB) (3 arms), sponsored by Xi'an Xintong Pharmaceutical Research Co., Ltd. Primary endpoints: Treatment-related adverse events at Day 7, Maximum Plasma Concentration (Cmax) at Day 4 and 6 more. Started Jul 2023; status: recruiting.
02
Drugs
XT1061
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06280534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06280534.